Establishing an Australian reference range for patients with Parkinson’s diseaseand healthy controls with F-DOPA Positron Emission Tomography.
Not Applicable
- Conditions
- Parkinson's diseaseNeurological - Parkinson's disease
- Registration Number
- ACTRN12618000386235
- Lead Sponsor
- Sir Charles Gairdner Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Parkinson's disease: based on the UK Brain bank clinical criteria and a Hoehn and
Yahr score of 2.5 or less (early PD) or 3.0 or more (late PD).
Normal controls: aged matched individuals with no historical or clinical evidence of
any neurological disorder.
Greater than 18 years of age
Able to undertake PET imaging
Able to provide written informed consent
Exclusion Criteria
Pregnancy
Less than 18 years of age
Medical contraindication to PET or MRI imaging
Patients with concurrent psychiatric disorders, signs of severe cognitive deterioration and severe cardiovascular comorbidity.
Cognitive impairment considered to impair the ability to give written informed consent in the opinion of the treating clinician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in the striatoccipital ratio (SOR) between health controls and Parkinson's disease (PD) subjects by assessment of FDOPA brain activity on PET scans. <br>[At completion of all subject imaging at the end of the study.]
- Secondary Outcome Measures
Name Time Method Estimate the diagnostic yield (sensitivity and specificity) of F-DOPA PET-CT scans in differentiating between normal healthy subjects and subjects with early and advanced-stage Parkinson's disease by assessing brain structures on MRI and brain activity on the FDOPA PET scan.[At completion of all subject imaging at the end of the study.];We will record any adverse events that occur in any group during the PET imaging process to assist in the assessment of the safety of F-DOPA PET imaging, although no adverse events from this procedure are anticipated..[At completion of all participant imaging.]